1. PRELIMINARY DATA ON LIVER TRANSPLANTATION IN HYDATIDOSIS DISEASE
- Author
-
Alexia Rangel de CASTRO, Elodie Bomfim HYPPOLITO, José Telmo VALENÇA-JÚNIOR, Gustavo Rego COELHO, and José Huygens Parente GARCIA
- Subjects
Echinococcosis, Hepatic ,Liver Transplantation ,Liver Diseases, Parasitic ,Surgery ,RD1-811 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
ABSTRACT - BACKGROUND: Hydatidosis is a rare and endemic parasitic disease in Brazil that causes the proliferation of cysts mainly in the liver, leading to many complications, such as compression of vessels and biliary ducts, liver failure, portal hypertension, and cirrhosis. The treatment of choice is the resection of the lesions combined with albendazole therapy. This disease is a rare indication for liver transplantation, a feasible treatment option in more advanced stages. AIM: The purpose of this study was to describe two cases of patients from northern Brazil who underwent liver transplantation due to hepatic hydatidosis. METHODS: This is a retrospective study with data collected from medical records. RESULTS: Case 1: A 51-year-old female patient presented pain in the right hypochondriac, dyspepsia, consumptive syndrome, and obstructive jaundice, with a previous diagnosis of Caroli’s disease with no possibility of surgical resection and a MELD score of 24. She underwent liver transplantation, and the anatomopathological result demonstrated hydatidosis. Case 2: A 52-year-old female patient presented multiple episodes of cholangitis in 30 years, with three liver resections and clinical treatment with albendazole for hydatidosis. She underwent liver transplantation due to recurrent cholangitis with a MELD score of 20. Both patients underwent post-transplant clinical therapy with albendazole, had good outcomes, and remain in follow-up without complications after 5 and 96 months, respectively. CONCLUSION: The patients benefited from the procedure and have a good prognosis due to the absence of metastasis, early reintroduction of antiparasitic drugs, and continuous follow-up.
- Published
- 2022
- Full Text
- View/download PDF